pharma · Bladder (Urothelial, Transitional Cell) Cancer · Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) · RLMD
RELMADA THERAPEUTICS
RELMADA THERAPEUTICS, INC.
RELMADA THERAPEUTICS trial registry — 10 ClinicalTrials.gov studies with program phase, status, and indication context.
Coral Gables, USA HQ
2004 Founded
33 Employees
Public company Type
RLMD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Coral Gables, USA
- Founded
- 2004
- Employees
- 33
- Programs
- 6
- Drugs
- 5
- Patents
- 7
RELMADA THERAPEUTICS clinical trials
Registry index of 10 ClinicalTrials.gov studies linked to RELMADA THERAPEUTICS programs — each row shows trial ID, program name, phase, status, and indication.
RELMADA THERAPEUTICS trial registry — 10 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for RELMADA THERAPEUTICS.
-
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel — Phase 2
Clinical update -
NDV-01 (sustained-release gemcitabine-docetaxel) — Phase 3
Clinical update -
NDV-01 (sustained-release gemcitabine-docetaxel) — Phase 3
Clinical update -
REL-1017 — Phase 3
Clinical update -
REL-1017 — Phase 2
Clinical update -
REL-1017 — Phase 1
Clinical update
Trial registry
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT06663137CT.gov ↗
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Non Muscle Invasive Bladder Cancer
- NCT07313891CT.gov ↗
NDV-01 (sustained-release gemcitabine-docetaxel)
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
- NCT07342517CT.gov ↗
NDV-01 (sustained-release gemcitabine-docetaxel)
Bladder (Urothelial, Transitional Cell) Cancer
- NCT07464145CT.gov ↗
NDV-01 (sustained-release gemcitabine-docetaxel)
Bladder (Urothelial, Transitional Cell) Cancer